TABLE 3.
Anti-SARS-CoV-2 activity of a panel of nucleos(t)ide analogs in different cells for original and adapted virusesa
| Nucleos(t)ide analog | EC50 (μM) |
|||||
|---|---|---|---|---|---|---|
| Original virus |
Adapted virus |
|||||
| Vero E6 | Huh7.5 | Vero E6 | Huh7.5 | Calu-1 | A549 | |
| Remdesivir | 1.5 | 0.03 | 2.9 | 0.05 | 0.29 | 0.31 |
| Molnupiravir | ND | ND | ND | 8.5 | 2.7 | 1.3 |
| GS-6620 | ND | ND | ND | >25 | >25 | >25 |
| Galidesivir | ND | ND | ND | 48 | 58 | 24 |
| Sofosbuvir | ND | ND | ND | >50 | >50 | >50 |
| Uprifosbuvir | ND | ND | ND | >50 | >50 | >50 |
| Valopicitabine | ND | ND | ND | >50 | >50 | >50 |
| Mericitabine | ND | ND | ND | >50 | >50 | >50 |
| Ribavirin | ND | ND | ND | >50 | >50 | >50 |
| Favipiravir | ND | ND | ND | >50 | >50 | >50 |
a
For each compound, the antiviral activity in Vero E6, Huh7.5, Calu-1, or A549 cells is indicated by 50% effective concentration (EC50) values (micromolar). These values were inferred from concentration-response curves based on 6 replicates (GS-6620) or 3 replicates (all other compounds). All compounds were tested at noncytotoxic concentrations as described in Materials and Methods. “>50” or “>25” indicates that the maximum concentration tested was 50 or 25 μM and that no viral inhibition reaching 50% was observed at this concentration. ND, not done.